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ABSTRACT

KYRA GAROFOLO. The Analysis of Acute Stroke Clinical Trials with Responder
Analysis Outcomes. (Under the direction of VALERIE DURKALSKI).
Traditionally in acute stroke clinical trials, the primary outcome has been a
dichotomized modified Rankin Scale (mRS). The mRS is a 7-point ordinal scale
indicating a patient's level of disability following a stroke. Traditional analyses have
used a fixed dichotomization scheme, which dichotomizes' success' as an mRS of 0-1 or
0-2. This method fails to address the concern that stroke severity may impact the
likelihood of a successful outcome; subjects with mild strokes may achieve the defined
\ threshold for success more easily than subjects with severe strokes. Consequently,
subjects are unable to contribute equally to the estimation of treatment effect. Stroke
studies are increasingly turning to new statistical methods that make more efficient use of
available data, including responder analysis.
Responder analysis, also known as the sliding dichotomy, allows the definition of
success to vary according to baseline severity. This method puts patients on a more level
playing field, producing a more clinically relevant insight into the actual effect of
investigational stroke treatments. It is unclear whether or not statistical analyses should
adjust for baseline severity when responder analysis is used, as the outcome already takes
into account baseline severity. Through the use of simulations, this research compares
the operating characteristics of unadjusted and adjusted analyses in the responder analysis
scheme. We also compare the treatment effect estimates and their standard errors
between methods.

IV

Under various treatment effect settings, the operating characteristics of the
unadjusted and adjusted analyses do not appear to differ substantially. Power and type I
error were preserved for both the unadjusted and adjusted analyses. Our results suggest
that, under the given treatment effect scenarios, the decision whether or not to adjust for
baseline severity should he guided by the needs of the study rather than a strict guideline,
as type I error rates and power do not appear to vary largely between the methods.

v

CHAPTER 1: INTRODUCTION AND BACKGROUND

Stroke is a potentially debilitating medical event that affects approximately
800,000 people in the United States each year, leaving as many as 30% of its victims
permanently disabled 1• Given this level of impact, there is great demand for treatments
which significantly improve functional outcome following a stroke. To date, there have
been few successful trials for clinical treatment of acute stroke. In fact, only 3 treatments
in over 125 stroke trials have demonstrated positive results. These treatments include
intravenous tissue-type plasminogen activator (tPA) within 3 to 4.5 hours from stroke
onset, hemicraniectomy for malignant infarction, and coiling for aneurysmal
subarachnoid hemorrhage2,3.
One of the possible reasons for the excessive number of neutral or unsuccessful
stroke trials is the definition of successful outcome4 . In clinical trials, stroke outcome is
most commonly measured by the modified Rankin Scale (mRS) of global disability,
usually measured at 90 days following stroke occurrence. The mRS is a 7-point ordinal
scale that ranges from 0 (no disability) to 6 (death), and has been shown to be a valid and
reliable measure of functional outcome following a strokes. Past trials have
dichotomized mRS scores into "success" and "failure", where mRS scores of 0-1 (or 0-2)
were considered to be "successes" while scores greater than 1 (or 2) were considered to
be "failures," regardless of baseline stroke severity 6,7,8,9. This method fails to take into

account the understanding that baseline severity is highly correlated with outcome; a
subject with a mild baseline severity may make only a slight improvement but be
considered a success, while a subject who suffered a very severe stroke may make vast
improvement but still be considered a failure due to scoring above a 1 (or 2) on the mRS
at the study's end. In addition, traditional dichotomization does not capture small shifts
along the outcome scale, which may be the goal of some treatment trials, such as
neuroprotective agents and hemostatic agents in intracerebral hemorrhage 1o• Due to its
drawbacks, strict dichotomization does not make efficient use of the data collected. New
methods are evolving to make better use of the outcome data in stroke trials with the
I

hopes of providing higher sensitivity to detect true treatment effects. These new methods
include the global statistic, shift analysis, permutation testing, and responder analysis.
1.1. New Endpoints and Analysis Methods
1.1.1. The global statistic.

In addition to the mRS, there are many other ordinal scales that assess stroke
outcome. These other scales include the National Institutes of Health Stroke Scale
(NIHSS), the Barthel Index (BI), the Glasgow Outcome Scale (GOS), and the Stroke
Outcome Scale (SOS); each of these is related to the others, but may capture a different
aspect of stroke functional outcome or disability. The global statistic consolidates several
of these measures into one outcome for analyses 6,1l. Though the tPA trials have been
reanalyzed and efficacy confirmed using additional statistical techniques, the original
outcome was defined by a global measure based on the dichotomization of the NIH
Stroke Scale, the Barthel Index, and the Glasgow Outcome Scale 12 ,13. Each of these
component scales was dichotomized regardless of baseline severity.
2

Analysis with a global statistic is particularly useful when no single outcome
sufficiently captures the desired endpoint 14 • One of the advantages of the global statistic
approach is that it allows for the simultaneous analysis of several outcome characteristics.
At the end of the analysis, rejection of the null hypothesis provides evidence for overall
treatment efficacy rather than efficacy in just one aspect of stroke outcome 11. ill addition,
there is often a power advantage when using the global statistic. By combining several
correlated measures of stroke outcome on the same subject, some of the noise observed in
the single scales alone is eliminated, thus increasing the ability to detect the true
treatment effect6 .
While the global statistic undoubtedly has its advantages, it has several
disadvantages as well. One major drawback of global statistic analysis is that its results
are difficult to translate into meaningful interpretations for physicians and patients 11 •
This aspect of the global statistic makes it less appealing, as any clinical study aims to
have clinically pertinent results at the study's end. In addition to questionable
interpretation, appropriate statistical methods for the analysis of the global statistic are
still evolving and often rely on dichotomization 6,11. Related methods such as principal
components analysis and multiple correspondences analysis have also been proposed
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but are highly statistically intensive and share the same interpretability disadvantages.

1.1.2. Shift analysis and the proportional odds model.
While the global statistic aims to combine several outcome measures into one
comprehensive measure, other methods aim to improve the analysis on a single ordinal
scale, such as the mRS. Where the traditional dichotomization method focuses only on
the distribution of scores on either side of one predetermined cutpoint, shift analysis
3

focuses on the distribution of study subjects across the entire ordinal scale. Rather than
asking whether the treatment makes more patients achieve a good outcome, defined as
better than threshold X, as in traditional dichotomized analyses, shift analysis asks the
question, "does the treatment make the patient better to some degree?,,6
Shift analyses are advantageous when prior knowledge of an appropriate cutpoint
is not available, as the entire scale is examined. In trials where the treatment effect tends
to be basically uniform across a large portion of the ordinal outcome scale or where the
treatment effect is clustered at an unexpected cutpoint, shift analysis has been shown to
be more powerful and more efficient than traditional dichotomization methods 6,I O ,4,9.
\ Another advantage of shift analysis is that it does not let baseline stroke severity limit the
ability of subj ects to contribute to the estimation of treatment effect 6.
Disadvantages of shift analysis include the assumptions of its statistical methods,
which may not be met in real studies 2,4. These assumptions include the "proportional
odds assumption" when proportional odds modeling is used, which assumes that the odds
ratio for a better outcome is the same at every cutpoint on the scale, and the assumption
that the treatment effect occurs only in one direction along the outcome scale 4,16.
Interpretations from shift analyses can also be difficult and are usually stated in terms of
number needed to treat (NNT) or combined odds ratios 2,6,4. The NNT in a shift analysis
setting is not as straightforward as in the dichotomized endpoint setting, as derivation of a
NNT across an entire ordinal scale must take into account within -patient correlation and

the fact that some transitions (such as transitioning from death to a vegetative state) are
considered unfavorable by patients 6. Joint outcome tables can be used to derive a
composite measure of the number of patients needed to treat for a single additional
4

patient to benefit, which can be used as a measure of treatment efficacy in shift analysis
studies.
1.1.3. Permutation testing.

One of the more recently proposed approaches to handle ordinal data in stroke
trials is that of permutation testing 17 . This method, proposed in 2012 by Howard et ai, is
similar to the Mann-Whitney Utest in that both methods nonparametrically investigate
the idea of whether a randomly chosen individual from one treatment group has a better
outcome than another randomly chosen person from another treatment group. However,
unlike the Mann-Whitney U test, the permutation method considers only untied pairs of
I

study subjects, primarily for the sake of interpretation. The permutation method, like
most statistical tests, bases its results on a test statistic calculated from the observed data.
This test statistic is compared to the estimated distribution of test statistics under the null,
which is derived under an iterative process which randomly assigns treatments to
individuals assuming no association between the test statistic and treatment.
The primary advantage of this approach is its ease of interpretability. When using
the permutation testing approach, the efficacy results can be explained simply in terms of
the proportion of people who will do better on the experimental treatment, compared to
the proportion who will do better on placebo and the proportion who will do the same on
either treatment 17. Another primary advantage is that this method is nonparametric, and
makes no distributional assumptions that must be met for validity. The permutation
testing method takes into account changes across the entire spectrum of an ordinal scale
such as the mRS, addressing the issues of traditional dichotomization of such scales. In
addition, the permutation method easily allows the incorporation of stratification of
5

important covariates. One potential disadvantage of this method is its relatively more
complex computing requirements when compared to similar methods such as the MannWhitney U test, which produce similar results.
1.1.4. Responder analysis.

As previously mentioned, a major problem with the traditional dichotomization
technique is that it fails to account for baseline severity. Responder analysis, also known
as the sliding dichotomy, still dichotomizes the outcomes into "success" and "failure,"
but addresses this issue by allowing cutpoints to vary. The definition of successful
outcome differs by prognosis group; those study subjects in a less severe prognosis group
I

at baseline must achieve a better outcome to be considered a trial "success," whereas
study subjects in a more severe baseline prognosis category must achieve a less stringent
criterion for success.
Within the responder analysis framework, there are different ways to determine
prognosis groups and success cutpoints. Prognosis groups may be determined by as few
as one baseline measure, such as the baseline NIHSS score, or the combination of many
baseline measures into one prognosis score by means of an algorithm 16,13 ,18,19,20. Often
times, cutpoints for success will be predetermined as in the AbESTT-II trial and
reanalysis of the NINDS-tP A trials 2o, 13. Each of these trials classified subjects into mild,
moderate, and severe baseline prognosis groups based on NIHSS scores, and defined
success as having a 3-month mRS=O for subjects in the mild, mRS<l for subjects in the
moderate, and mRS<2 for subjects in the severe prognosis groups. Alternatively, some
studies determine these thresholds based on the empirical distribution of the data and the
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probabilities for success within each of the prognosis groups, as in the simulation study
based on the IMP ACT Proj ect results 16.
One advantage of responder analysis when compared to the traditional
dichotomization method is that it allows each subject to have an achievable goal based on
their baseline severity. By allowing the definition of success to vary with severity, the
ability to detect a true treatment effect is increased without increasing external noise and
variability6. Responder analysis is a relatively computationally easy method to employ
and has been argued to be more powerful than traditional dichotomization methods 8,I6,18.
However, a direct comparison of the traditional dichotomization method with responder
I

analysis in the same data must be interpreted with caution, as the control rates in the two
cases are not the same by definition, and thus the power comparison may not be
appropriate.
While responder analysis has its advantages, there are potential disadvantages to
consider as well. Like traditional dichotomization, the ordinal outcome is still collapsed
into a dichotomous outcome, thus discarding information about specific mRS categories.
In addition, for responder analysis to be most effective, investigators must carefully
define appropriate prognosis groups and their respective cutpoints for success 6.
The global statistic, shift analysis, the permutation method, and responder
analysis are several of the new methods being employed in stroke clinical trials to
overcome the drawbacks of traditional dichotomization. Each of these methods has its
own advantages and disadvantages as discussed above. The most appropriate method
will depend on the aims of the clinical trial; investigators should consider the unique
aspects of their clinical trial when determining the primary analysis technique.
7

1.2. Covariate Adjustment
Statistical analyses often adjust for prognostic factors, or covariates that may be
predictive of the primary outcome. One philosophy that motivates covariate adjustment
is that it can confirm that the observed treatment effect is "independent" of these
21
prognostic factors, rather than artificially created by confounding prognostic factors .
Another motivation for covariate adjustment is possible covariate imbalance. While
covariate adjustment can help temper the effects of a covariate imbalance, it should not
be used as a means to address imbalance in baseline characteristics between treatment
groups22. Instead, the study design should strive to prevent covariate imbalance
whenever possible. Adjustment for important covariates also accounts for additional
variation in the data. Accounting for this additional variation can lead to increased
statistical efficiency, which is a primary reason for covariate adjustment during analysis.
In the case of a continuous outcome and classical linear regression, covariate adjustment
may increase the precision of a treatment effect estimate, as it may decrease the standard
23
error of the estimate due to a reduction in residual variance .
An interesting phenomenon occurs when logistic regression is used in the case of
a binary outcome, as in the traditional or sliding dichotomy settings. Covariate
adjustment in the case of logistic regression results in a loss of precision of the treatment
effect estimate, as the standard error on the treatment effect estimate is increased.
However, this increase in standard error is balanced by a movement of the treatment
effect estimate away from the null hypothesis. This phenomenon was described by
Robinson and Jewell, who concluded that "it is always as or more efficient to adjust for
the covariate when logistic regression is used,,23.
8

1.3. Our Motivation
We wanted to investigate the effect of covariate adjustment in the responder
analysis framework, particularly when the covariate is involved in the definition of
successful outcome. This problem was first posed by the data and safety monitoring
board for the SHINE Trial (discussed below), which questioned whether adjusting for the
prognostic variable twice-in the definition of success and in the analysis-would impact
the test of treatment effect. Since the literature does not directly address this issue, we
used the SHINE Trial as a basis for a simulation study to explore the consequences of
covariate adjustment under the responder analysis framework.
1.3.1. The SHINE Trial

The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial is a large,
multicenter, randomized clinical trial to determine the efficacy and safety of targeted
glucose control in hyperglycemic acute ischemic stroke patients. Approximately 1400
subjects will be enrolled and randomized to receive either standard of care or targeted
glucose control. To be eligible for the

study~

subjects must be enrolled within 12 hours of

symptom onset and within 3 hours of Emergency Department arrival, as well as have a
blood glucose concentration greater than 110 mg/dL on initial evaluation. Baseline
stroke severity must fall between 3 and 22 (inclusive) on the NIHSS. Subjects in the
standard of care treatment arm receive subcutaneous and basal insulin injections
according to a sliding scale with a target blood glucose of < 180 mgldL; subjects in the
intervention arm receive up to 72 hours of intravenous insulin infusion with a target
blood glucose between 80 and 130 mgldL.

9

The primary outcome for efficacy in the SHINE trial is the 90-day mRS score.
Outcome is dichotomized as "success" or "failure" according to a sliding dichotomy.
Those with a "mild" prognosis, defined by a baseline NIHSS score of 3-7, must achieve a
90-day mRS of 0 to be classified as a "success." Those with a "moderate" prognosis,
defined by a baseline NIHSS score of 8-14, must achieve a 90-day mRS of 0-1 to be
classified as a "success." Finally, those subjects with a "severe" prognosis, defined by a
baseline NIHSS score of 15-22, must achieve a 90-day mRS of 0-2 to be classified as a
"success." By using responder analysis, the milder strokes must meet a more stringent
threshold to achieve success, while the more severe strokes have more leeway to achieve
an attainable definition of success. Two pilot studies, THIS and GRASP, were used to
establish the initial safety and efficacy estimates of intensive glucose control in
2425
. stro ke patIents
.
' .
hyperg Iycemlc

1.4. Specific Aims
The focus of this research is covariate adjustment within the responder analysis
framework, as the SHINE trial employs responder analysis in its primary statistical
analyses. While the literature provides many resources on the design and implementation
of responder analysis as well as examples of trials which used responder analysis, there
are no clear resources supporting whether or not statistical analyses should be adjusted
for the prognostic variables used to define successful outcome. The cutpoints for the
SHINE trial are clinically, rather than statistically defined, and so it is conceivable that
adjustment for baseline severity in the statistical analysis may account for additional
variation. Through simulations, we aimed to explore the results of covariate adjustment

10

in the responder analysis setting. Our simulation parameters are based on those specified
in the SHINE trial. The goals of this study were:
•

To compare the operating characteristics of unadjusted and adjusted analyses
under several different treatment effect scenarios in the responder analysis setting
when treating baseline severity as a categorical variable with three levels.

•

To compare the treatment effect estimates and their standard errors in unadjusted
and adjusted analyses under several different treatment effect scenarios.

Since the primary outcome for the SHINE trial is binary, we expected to see an increase
of standard error on the treatment effect estimates, consistent with the findings of
Robinson and JeweU 23 .
1.5. Significance
It is unclear whether or not statistical analyses should further adjust for those
covariates involved in the definition of favorable outcome in trials that use responder
analysis, such as the SHINE trial discussed above. The results of this study will help
demarcate the best way to handle such analyses. These results will not only be applicable
in the SHINE and other stroke trials which use the mRS for the primary outcome, but
also in other trials which use any ordinal scale as a primary outcome measure and have a
baseline prognostic factor.

11

CHAPTER 2: THE SIMULATION STUDY

We performed several simulation analyses where we examined the performance
of logistic regression models that were unadjusted and adjusted by baseline severity
category. Baseline severity category was defined as in the SHINE Trial described above:
an mRS score of 3-7 was defined as "mild," 8-14 was defined as "moderate," and 15-22
was defined as "severe." As in the SHINE study plan, subjects in the mild group must

°

achieve a 90-day mRS of 0, moderate must achieve a 90-day mRS of or 1, and severe
must achieve a 90-day mRS of 0, 1, or 2 to be considered a success. The type I error rate
and power were calculated and compared for each method, as were the treatment effect
estimates and their standard errors.

2.1. Simulation Methods
The simulation parameters were guided by the SHINE trial design. We simulated
1000 clinical trials at sample sizes 498 to 1958. This sample size range allows us to
cover the planned sample size of 1400 while also examining model behavior at smaller
and larger sample sizes. Though the SHINE study may begin response-adaptive
randomization at some point during enrollment, we have assumed a 1: 1 randomization
scheme for the purposes of our investigation. All analyses were performed using SAS
version 9.2 (SAS Institute, Cary, North Carolina).

The prevalence of each baseline severity category was guided by the THIS and
GRASP pilot trial data24 ,25. The pilot trials had similar distributions of baseline severity
categories, and thus it is reasonable to assume that the SHINE study population will have
a similar distribution. In our simulations, we have assumed that 42% of subjects will be
classified as "mild" at baseline, 32% will be classified as "moderate" at baseline, and the
remaining 26% will be classified as "severe" at baseline. These classifications were
randomly assigned using a uniform [0,1] random variable.
The simulation of study outcome (90-day mRS) differed by treatment group. In
order to simulate 90-day mRS scores for the control group, we examined the distribution
of90-day mRS scores for the control groups in the THIS and GRASP pilot trials. Since
these trials were both very small, we could not derive a good approximation of the
distribution of mRS scores in each of the baseline severity strata. We used the control
group from the NINDS tPA trial data to help in the approximation of mRS distributions 12 •
The control group distribution of 90-day mRS scores used in this simulation study is
shown in Table 1.

Table 1: Distribution oi90-Day mRS Scores for Control Group
Baseline
90-Day mRS
Severity
3
4
0
1
2
0.25
0.20
0.10
0.30
0.08
Mild
0.23
0.15
0.20
0.12
0.16
lVIoderate
0.03
0.05
0.07
0.19
0.20
Severe

0.02
0.04

6
0.05
0.10

0.21

0.25

5

Type I error rates for each method were obtained by using the distribution of 90day mRS scores found in Table 1 for both the control and intervention groups, simulating
the null hypothesis of no treatment effect. In order to assess the power of each method, a
13

treatment effect was simulated in the data by altering the distribution of 90-day mRS
scores in Table 1 for the intervention group only. We added a 7% treatment effect, as
this was the minimum clinically significant difference defined in the SHINE study plan.
For these analyses, we only examined power under several different treatment effect
scenarios: (1) a "flat" treatment effect scenario, in which a 7% treatment effect was
applied in each baseline severity stratum; (2) a "varying" treatment effect scenario, in
which there is still an overall 7% treatment effect, but the magnitude within strata varies
and the mild and moderate groups see the most benefit; (3) a "varying" treatment effect
scenario, in which there is still an overall 7% treatment effect, but the severe group sees
the most benefit; (4) a "mild harm" treatment effect scenario, in which there is still an
overall 7% treatment effect, but the mild group sees a harmful treatment effect; and (5) a
"severe harm" treatment effect scenario, in which there is still an overall 7% treatment
effect, but the severe group sees a harmful treatment effect.
The flat treatment effect was achieved by allowing 70/0 more prevalence in the
defined "success" mRS categories for each stratum. In the first varying treatment effect
scenario, we applied an 8.6% treatment effect in the mild category, a 90/0 treatment effect
in the moderate category, and a 2% treatment effect in the severe category; that is, there
was an 8.6% increase in prevalence of the 0 mRS for the mild stratum, a 9% increase in
the prevalence of the 0-1 range of mRS scores for the moderate stratum, and a 2%
increase in the prevalence of the 0-2 range of mRS scores for the severe stratum. This
scenario is relevant for the SHINE trial; it is similar to what we may observe if the
intensive glucose control intervention is largely beneficial to mild and moderate stroke
victims, but only marginally beneficial to victims of severe stroke. Similarly, in the
14

second varying treatment effect scenario, we applied a 2% treatment effect in the mild
category, a 9% treatment effect in the moderate category, and a 12.6% treatment effect in
the severe category. This scenario could also be observed in the SHINE results if the
intensive glucose control intervention is largely beneficial to more severe strokes, but
only slightly beneficial to those subjects having mild strokes. Tables 2, 3, and 4 show the
distribution of 90-day mRS scores for the treatment groups under these flat and varying
treatment effects, respectively.

Table 2: Distribution o/90-Day mRS Scores/or Treatment Group:
HFlat" Treatment Effect
Baseline
90-Day mRS
Severity
0
1
3
4
5
2
0.08
0.32
0.27
0.19
0.07
0.02
Mild
0.17
0.10
0.15
0.25
0.21
0.03
Moderate
0.18
0.04
0.06
0.12
0.18
0.19
Severe

Table 3: Distribution o/90-Day mRS Scores/or Treatment Group:
First "Varying" Treatment Effect
Baseline
90-Day mRS
Severity
0
1
3
2
4
5
0.336
0.31
0.19
0.06
0.04
0.02
Mild
0.19
0.25
0.25
0.10
0.10
0.02
Moderate
0.20
0.03
0.055
0.19
0.20
0.085
Severe

Table 4: Distribution o/90-Day mRS Scores/or Treatment Group:
Second HVarying" Treatment Effect
Baseline
90-Day mRS
Severity
1
2
3
4
0
5
0.31
0.20
0.09
0.27
0.06
0.02
Mild
0.19
0.25
0.25
0.10
0.10
0.02
Moderate
0.146
0.18
0.04
0.09
0.12
0.194
Severe
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6
0.05
0.09
0.23

6
0.044
0.09
0.24

6

0.05
0.09
0.23

To achieve the scenarios in which one of the strata experienced harm, we applied
similar effects as above, only allowing one of the strata to see a decrease in the
prevalence within its defined success categories. In the "mild harm" scenario, we applied
a -2% treatment effect in the mild category, with a 15% treatment effect in the moderate
category and an 11.7% treatment effect in the severe category. Similarly, in the "severe
harm" scenario, we applied an 8% treatment effect in the mild category, a 130/0 treatment
effect in the moderate category, and a -2% treatment effect in the severe category. Either
of these scenarios could possibly be observed in SHINE if the intervention if the
intensive glucose control interferes with the body's natural recovery processes following
a milder or more severe stroke, respectively. Tables 5 and 6 show the distribution of 90day mRS scores for the mild and severe harm scenarios.

Table 5: Distribution o/90-Day mRS Scores/or Treatment Group:
"Mild Harm" Treatment Effect
Baseline
Severity

0

1

Mild

0.23

0.29

Moderate

0.20

0.30

Severe

0.05

0.09

90-Day mRS

2
0.21
0.20
0.127

3

4

5

0.12

0.08

0.02

0.08

0.10

0.03

0.13

0.16

0.20

6
0.05
0.09
0.243

Table 6: Distribution o/90-Day mRS Scores/or Treatment Group:
"Severe Harm " Treatment Effect
Baseline
Severity

0

Mild

0.33

Moderate

0.20

Severe

0.02

90-Day mRS

1
0.29
0.28
0.04

2
0.15
0.18
0.07

16

3

4

0.09

0.07

0.11

0.12

0.20

0.21

5
0.03
0.03
0.21

6
0.04
0.08
0.25

The distributions in Tables 1 through 6 were used to randomly assign 90-day
mRS scores to each simulated subject in each simulated trial. The distribution in Table 1
was used for the control group, regardless of the treatment effect scenario being
examined. When no treatment effect was applied in order to investigate type I error rates,
Table 1 was used for the intervention group as well. The distributions in Tables 2
through 6 were used to assign mRS scores to subj ects in the intervention group in order to
investigate power under fixed and varying treatment effects, respectively. Given a
subject's simulated baseline severity stratum (mild, moderate, or severe), an assignment
of "success" or "failure" was made according to the sliding dichotomy definitions.
Logistic regression was used to investigate each of these scenarios. We examined
unadjusted and categorically-adjusted analyses for each scenario. The unadjusted case
models "success" as a function of only treatment group, while the categorically-adjusted
case models "success" as a function of treatment group and severity category. For the
power and type I error rate estimation, we created an indicator variable to denote the
rejection of the null hypothesis for each of the 1000 simulated trials at a given sample
size. The proportion of simulated trials at a given sample size which were rejected is our
power/type I error rate estimation at that sample size. We also extracted the treatment
effect estimate and its standard error for each trial.
2.2. Results

2.2.1. Type I error rates and power.
The type I error rate (significance level) at each sample size for each method is
plotted below in Figure 1. The nominal 50/0 reference line is shown, as well as upper and
lower 95% confidence limits on this nominal level. The confidence limits were
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calculated using the fonnula for binomial proportion 950/0 confidence intervals, yielding
the following equation:
P+
- ZO.975

Jp(l-P)
n

0 05 + 1 96
==.
-'

0.05(1-0.05) =
1000

(0.0365 0.0635)
'

These confidence limits were then multiplied by 100 to be expressed in terms of
percentages. The sample size is 1000, since we have simulated 1000 trials at each sample
size in order to get our significance level estimates.

Figure J: Significance Levels of Unadjusted and Categorically-Adjusted Methods

Estimated Level of Significance
No Treatment Effect
o:£

10

9
8
7

6 ~------------------------------------------------------~

5 ~~~~~~~~-------~----~~~~~~~~~~~--~
4 ~

____________~~~~___~~________________________~

3
2
1
O~~~~~~~~~~~~~~~~~~~~~~~~~~~~
200

250

300

350

400

450

500

550

600

650

700

750

800

850

900

950

1000

Sample Size per Group
Method

........

Unadjusted Analysis

/s--h;--A

Categorically-Adjusted .A.nalysis

We can observe that both the unadjusted and categorically-adjusted methods have
type I error rates within the 950/0 confidence bounds at each sample size. This is a
welcomed result, as an inflated type I error rate results in a test that is too liberal, while a
deflated type-I error rate results in a decrease in power and thus a test that is too
conservative. The oscillation around the nominal 5% level of significance is due to
chance, and is to be expected in experimental or simulated data. Since neither method
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shows consistently larger type I error rates, we can conclude that there is no meaningful
difference between the two methods with respect to significance level under the chosen
treatment effect setting.
Our first investigation of power was under a "flat" treatment effect, in which each
of the three prognosis groups experienced a simulated 7% treatment effect. The success
rates in the control group were 25%, 35%, and 150/0 in the mild, moderate, and severe
prognosis groups, respectively. These control rates are based on the pilot trials for
SHINE, and their distributions are further detailed in Table 1. The power estimates for
this "flat" treatment effect scenario are plotted in Figure 2 below. Under a true treatment
effect of 7%, the SHINE study is designed to have at least 800/0 power, which is
referenced along the plot in Figure 2.

Figure 2: Power of Unadjusted and Categorically-Adjusted Methods Under a Flat 7%
Treatment effect
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Categorically-Adjusted Analysis
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The unadjusted and categorically-adjusted methods do not appear to differ
significantly in the plot in Figure 2. The two methods are nearly stacked in most places,
with the categorically-adjusted method having very slightly greater power along much of
the plot. As planned by the SHINE study investigators, the 80% power threshold is
crossed between 650 and 700 subjects per arm (1300-1400 subjects total). The slight
appearance of powering beyond the 80% level at the planned 1400 total subjects is
expected, as the sample size estimation was slightly inflated for potential non-adherence.
Though our results from the simple flat treatment effect scenario were a good
starting point, it is unlikely that we will see a uniform treatment effect across all strata in
practice. To continue our investigation under an alternative scenario, we next considered
the possibility of a treatment effect that varies across prognosis strata, but maintains the
overall 7% treatment effect. We first allowed the mild, moderate, and severe baseline
categories to have treatment effects of 8.6%, 9%, and 2%, respectively. Then, we
allowed the mild, moderate, and severe baseline categories to have treatment effects of
2%, 9%, and 12.6%, respectively. The power results for these two scenarios are plotted
in Figures 3 and 4.
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Figure 3: Power of Unadjusted and Categorically-Adjusted Methods Under the First
Varying 7% Treatment effect
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Figure 4: Power of Unadjusted and Categorically-Adjusted Methods Under the Second
Varying 7% Treatment effect

Estimated Power
Varying Treatment Effect by Prognosis Group
Mild 2%, Moderate 9%, Severe 12.6% Treatment Effect
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As in the flat treatment effect scenario, we do not see a drastic difference in the
unadjusted and categorically-adjusted methods with respect to power in these varying
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treatment effect scenarios. There is a slightly larger gap between the categoricallyadjusted and unadjusted methods' power curves at points in Figures 3 and 4 when
compared to Figure 2, but the difference is not remarkable. It is reassuring, however, that
we do not observe a noticeable decrease in power under the varying treatment effects for
either method; this will be especially important if the study data reveals that the treatment
effect truly does vary by prognosis stratum in either of these manners.
As previously mentioned, it is conceivable that one of the prognosis groups may
experience a slightly harmful treatment effect. To investigate the consequences of
adjusting for baseline severity in this situation, we examined scenarios in which the mild
and severe groups experienced a -2% treatment effect. The results of these simulations
are in Figures 5 and 6.

Figure 5: Power of Unadjusted and Categorically-Adjusted Methods Under a Mild
Harm Effect
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Figure 6: Power of Unadjusted and Categorically-Adjusted Methods Under a Severe
Harm Effect
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When 2% harm is experienced in either the mild or the severe baseline prognosis
category, the unadjusted and adjusted analyses still appear to perform very similarly. In
the mild harm scenario, the unadjusted and adjusted power curves are still nearly stacked
upon one another, with the power curve for the adjusted analysis pulling slightly above
that of the unadjusted analysis at a few points. A more noticeable difference can be seen
in the severe harm scenario, where the adjusted analysis consistently has a slightly higher
power than that of the unadjusted analysis. Though the power appears to be slightly
higher for the adjusted analysis, this difference is still not very remarkable, and offers
little evidence to suggest that adjusting is significantly more powerful under this scenario.

2.2.2. Treatment effect estimates and their standard errors.
In addition to the plots in Figures 2 through 6, we also observed the treatment
coefficient estimates and their standard errors for the adjusted and unadjusted models in
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the various treatment effect scenarios. The coefficient and standard error estimates are
averaged over all simulations and all sample sizes, and are displayed in Table 7.

Table 7: Treatment Coefficient Estimates and Their Standard Errors for Unadjusted
and Adjusted Methods Under Different Treatment Effect Scenarios
Scenario
"Flat"
1st Varying
2nd Varying
Mild Harm
Severe Hann

Unad·usted
Ptrt Estimate
SE (Ptrt)
0.3430275
0.1378434
0.3427666
0.1379159
0.1377643
0.3404175
0.3409949
0.1377578
0.3408927
0.1377668

Adjusted
fltrt Estimate
SE (fltrt)
0.3535594
0.1401410
0.3577844
0.1410730
0.3504053
0.1400125
0.1411719
0.3568029
0.1419651
0.3610773

As expected, we observed a slight inflation of the standard errors when adjusting.
This phenomenon, first described by Robinson and J ewelf 3, is balanced by a slight
increase in magnitude of the treatment coefficient estimate away from the null. It is this
reciprocating increase that preserves (and may slightly increase) our power in the case of
adjustment for categorical baseline severity.
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CHAPTER 3: DISCUSSION

Successful stroke treatments are in high demand given stroke's large and
detrimental effect on the worldwide population. Consequently, statistical methods that
offer higher power to detect a true treatment effect are also in high demand, especially
given the large number of unsuccessful stroke trials to date, and the consideration that
many of these unsuccessful stroke trials may have failed due to study design. With this
simulation study, we sought to determine whether adjustment for baseline severity within
the responder analysis setting would be beneficial or harmful in terms of power and type
I error rates when compared to an unadjusted analysis.
The results in Chapter 2 show little evidence for or against adjusting for baseline
severity in the responder analysis setting. The type I error rates between the two methods
did not seem to differ substantially, and the power curves for most treatment effect
scenarios examined were practically identical for the adjusted and unadjusted methods.
In the case where the interventional treatment caused slight harm to the severe baseline
group, the power for the adjusted analysis consistently appeared to be slightly greater
than that for the unadjusted analysis; however, this difference was small and not
noteworthy. These results suggest that in most treatment effect scenarios, adjustment for
baseline severity in the primary analyses may best be guided by individual study needs
rather than a blanket guideline for all studies, as neither the adjusted nor unadjusted

method showed notable statistical advantage in our examples. As in any clinical trial
setting, sensitivity analyses can be conducted with the alternative approach to provide
confirmation of the results found in the primary analyses.
Though we have not shown the results here, we did examine other treatment
effect scenarios which also yielded similar results. These scenarios included a flat and
varying 15% treatment effect (instead of the 7% specified in the SHINE study plan), as
well as a scenario in which the mild group experienced 5% harm. In the 15% treatment
effect scenarios, the two methods were practically non-differentiable, as even at the
smallest sample sizes examined the study was overpowered for such a large effect and the
graphs plotted on top of one another. The 5% mild harm scenario yielded very similar
results to those seen in Chapter 2 with the 2% mild harm. Given that none of these
results uniquely contributed to our conclusion, we have omitted their results here in
interest of space.
It is important to note that these analyses adjust for baseline severity
categorically. These categories-mild, moderate, and severe-are defined by the NIHSS
score, which is a larger ordinal scale ranging from 0 to 42 (limited to 3 through 22 in
SHINE's inclusion criteria). It is possible that adjusting by the actual NIHSS score will
provide additional information to the model and increase or maintain power in some
treatment effect scenario(s). Though the NIHSS is technically an ordinal scale, it is
sometimes used as a continuous measure in the literature 26,27. However, interpreting the
NIHSS as a continuous measure is not necessarily straightforward and should be done
with caution; a one-unit increase on the NIHSS at one location on the scale may not have
the same implications as a one-unit increase in another location. Development of a
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simulation study to investigate adjustment for baseline severity continuously by NIHSS
compared with categorically-adjusted and unadjusted analyses has been proposed as
future work.
3.1. Future Work
As discussed above, future work will include the investigation into adjustment by
NIHSS as a continuous covariate. Though SHINE uses only baseline severity category to
define success, some studies-including the GRASP pilot trial for SHINE- use multiple
baseline characteristics in a prognostic model to define success thresholds, as discussed
in Section 1.1.425. Future work could potentially involve the exploration of adjusting for
these baseline characteristics when they are used in such a prognostic model. This study
was performed under a perfect one-to-one treatment allocation rate, but we may also use
our simulations to investigate how an imbalance in treatment allocation impacts the
analyses. Allowing the prevalence within each of the baseline severity categories to vary
from what was observed in the pilot trials may also provide interesting results, since
baseline severity dictates the definition of successful outcome in responder analysis.
When the SHINE Trial concludes, a repeat of these analyses using the actual data may be
used to confirm our findings. In addition, future work may include the establishment of
the theoretical basis for our findings.
Our immediate next step is to explore the various analysis techniques on a
publicly-available clinical trial dataset. We aim to compare not only the unadjusted and
categorically-adjusted analysis methods in the responder analysis settings, but then also
compare these methods with other analysis techniques available for ordinal data. This
comparison will help us verify (or dispute) our findings with respect to adjusting in the
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responder analysis setting as well as look at the difference in statistical power between
responder analysis and other statistical analysis techniques.
3.2. Conclusion
There does not appear to be an impact in terms of statistical operating
characteristics whether the analyses are unadjusted or adjusted by baseline severity
category in the treatment effect scenarios examined in this simulation study. While we
had hoped to find that one of the two methods had significantly greater power, it should
be noted that these results are not negative. Instead, they suggest that adjustment by
baseline severity category is a matter of individual study needs and has little effect on the
statistical operating characteristics of the analysis. These results are not restricted to use
in stroke studies; they are generalizable to any type of study which uses responder
analysis to define its primary outcome of interest.
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APPENDIX: SIMULATION SAS CODE
Included below is the SAS code for the macro that is used to create each dataset
under the various scenarios. In addition, I have included how it would be used in the case
of no treatment effect in order to examine type I error rates. Other treatment effect
scenarios can be attained similarly by changing the prevalence cutoffs for the mRS
distribution, as described in Tables 1 through 6.

%macro
simulatetrial(sarnpsize=,Cmildl=,Crnild2=,Crnild3=,Crnild4=,Cmild5=,Cmild6=
,Cmodl=,Cmod2=,Cmod3=,Crnod4=,Cmod5=,Cmod6=,Csevl=,Csev2=,Csev3=,Csev4=,
Csev5=,Csev6=,Trnildl=,Tmild2=,Tmild3=,Tmild4=,Tmild5=,Tmild6=, Tmodl=, Tm
od2=, Tmod3=, Tmod4=, Tmod5=, Tmod6=,Tsevl=,Tsev2=,Tsev3=, Tsev4=,Tsev5=,Tse
v6=) ;

data simulatedtrial;
do i=l to &sampsize;
half=&sampsize/2;
if i Ie half then trt='A';
else trt='B';
rand_prog=ranuni (80272+&nsim);
k
~::;tp p~<)qC:)SL':3 \_~.
p;
if rand_prog Ie 0.42 then prognosis=l;
else if rand_prog gt 0.42 and rand_prog Ie 0.74 then prognosis=2;
else if rand_prog gt 0.74 and rand_prog Ie 1.0 then prognosis=3;
else prognosis=999; * ~;a.fr.:::Tla r,~j ~'J:<:K;
output;
end;
run;
data simulatedtrial;
set simulatedtrial;
uniform=ranuni(20453+&nsim);
if trt='A' then do;
if prognosis=l then do;
if uniform Ie &Cmildl then simrankin=O;
else if uniform> &Cmildl and uniform Ie &Crnild2 then simrankin=l;

else if uniform> &Cmild2 and uniform Ie &Cmild3 then simrankin=2;
else if uniform > &Cmild3 and uniform Ie &Cmild4 then simrankin=3;
else if uniform> &Cmild4 and uniform Ie &CmildS then simrankin=4;
else if uniform > &Cmild5 and uniform Ie &CmiId6 then simrankin=5;
else if uniform > &Cmild6 then simrankin=6;
if simrankin=O then stratout=l
*
~~ if'
else stratout=O;
end;
if prognosis=2 then do;
if uniform Ie &Cmodl then simrankin=O;
else if uniform > &Cmodl and uniform Ie &Cmod2 then
else if uniform > &Cmod2 and uniform Ie &Cmod3 then
else if uniform > &Cmod3 and uniform Ie &Cmod4 then
else if uniform > &Cmod4 and uniform Ie &CmodS then
else if uniform > &Cmod5 and uniform Ie &Cmod6 then
else if uniform > &Cmod6 then simrankin=6;
k T'"~: >~ ~~. L ~.~
if simrankin Ie 1 then stratout=l;
else stratout=O;
end;

simrankin=l;
simrankin=2;
simrankin=3;
simrankin=4;
simrankin=5;
-_.

. . 1-:: :; :: ;

if prognosis=3 then do;
if uniform Ie &Csevl then simrankin=O;
else if uniform > &Cievl and uniform Ie &Csev2 then simrankin=l;
else if uniform > &Csev2 and uniform Ie &Csev3 then simrankin=2;
else if uniform > &Csev3 and uniform Ie &Csev4 then simrankin=3;
else if uniform > &Csev4 and uniform Ie &CsevS then simrankin=4;
else if uniform > &Csev5 and uniform Ie &Csev6 then simrankin=5;
else if uniform > &Csev6 then simrankin=6;
if simrankin Ie 2 then stratout=l;
*Detl!:~E';':·. _ ,,_>~P~3S;
else stratout=O;
end;
end;
else if trt='B' then do;
if prognosis=l then do;
if uniform Ie &Tmildl then simrankin=O;
else if uniform > &Tmildl and uniform Ie &Tmild2
else if uniform > &Tmild2 and uniform Ie &Tmild3
else if uniform > &Tmild3 and uniform Ie &Tmild4
else if uniform > &Tmild4 and uniform Ie &TmildS
else if uniform > &Tmild5 and uniform Ie &Tmild6
else if uniform > &Tmild6 then simrankin=6;
!-:~;E:;lne s
if simrankin=O then stratout=l;
else stratout=O;
end;
1...'<

if prognosis=2 then do;
if uniform Ie &Tmodl then simrankin=O;
else if uniform > &Tmodl and uniform Ie
else if uniform > &Tmod2 and uniform Ie
else if uniform > &Tmod3 and uniform Ie
else if uniform > &Tmod4 and uniform Ie
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&Tmod2
&Tmod3
&Tmod4
&Tmod5

p'

then
then
then
then
then

simrankin=l;
simrankin=2;
simrankin=3;
simrankin=4;
simrankin=5;

-"

then
then
then
then

simrankin=l;
simrankin=2;
simrankin=3;
simrankin=4;

else if uniform> &Tmod5 and uniform Ie &Tmod6 then simrankin=5;
else if uniform > &Tmod6 then simrankin=6;
.:; ;
if simrankin Ie 1 then stra tout=l;
"'-'0'':: 1
else stratout=O;
end;
if prognosis=3 then do;
if uniform Ie &Tsevl then simrankin=O;
else if uniform > &Tsevl and uniform le &Tsev2
else if uniform > &Tsev2 and uniform Ie &Tsev3
else if uniform > &Tsev3 and uniform Ie &Tsev4
else if uniform > &Tsev4 and uniform le &Tsev5
else if uniform > &Tsev5 and uniform Ie &Tsev6
else if uniform > &Tsev6 then sirnrankin=6;
=. (-? : . 1 :'-~
if simrankin Ie 2 then stratout=l;
else stratout=O;
end;
end;
run;
.'c

:~) :<

,'~.~

(::; ·:3 .3 ;

(Adiuste)
proc logistic data=simulatedtrial descending
outest=logisticresults_strat_adj covout noprint
class trt prognosis (ref=last)/ desc param=reference;
model stratout=trt prognosis;
run;
~

gis:i2 Fe

simrankin=l;
simrankin=2;
simrankin=3;
simrankin=4;
simrankin=5;

then
then
then
then
then

~

3Sl

data estimate_strat_adj;
set logisticresults strat adj;
where type_="PARMS";
or_strat_adj=exp(trtB);
keep trtB or_strat_adj;
rename trtB=trtbeta strat ad];
run;
data variance strat_adj;
set logisticresults strat ad];
where type ="COV" and name ="trtB";
keep trtB;
rename trtB=var trtbeta strat ad];
run;
.-:) (~.i

+-

'I ;-'

C

~:J :~

s

v;

{-

,3.J -; ,

} ;

proc logistic data=simulatedtrial descending
outest=logisticresults_strat_un covout noprint
class trt prognosis (ref=last)/ desc param=reference;
model stratout=trt;
run;
data estimate - strat - un;
set logisticresults strat un;
where type_="PARMS";
or strat_un=exp(trtB);
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keep trtB or_strat_un;
rename trtB=trtbeta strat un;
run;
data variance strat un;
set logisticresults strat un;
where type ="COV" and name ="trtB";
keep trtB;
rename trtB=var trtbeta strat un;
run;
proc iml;
nsim=&nsim;
:: r a

+-

--....:.- .;:

c ...._

~_

use estimate strat_adj;
read all var {trtbeta strat adj} into beta_strat_adj;
read all var {or_strat_adj} into or strat adj;
use variance_strat_adj;
read all var {var_trtbeta_strat_adj} into var_beta strat_adj;
logistic_strat_adj_ts=(beta_strat_adj/sqrt(var_beta_strat adj))##2;
logistic strat adj reject=logistic strat adj ts>3.84;
use estimate strat un;
read all var {trtbeta strat un} into beta strat un;
read all var {or strat un} into or strat un;
use variance - strat - un;
read all var {var_trtbeta_strat un} into var beta_strat_un;
logistic_strat_un_ts=(beta_strat_un/sqrt(var_beta_strat un))##2;
logistic strat un reject=logistic_strat un ts>3.84;
use simulatedtrial;
read all var
read all var
read all var
read all var
ntrt= (trt=' A'

{prognosis} into prognosis;
{nihss} into nihss;
{trt} into trt;
{stratout} into stratout;
) [+ J; nplacebo= (trt=' B' ) [+]; *'

L=p

::1

t:.

::i=

d

::t 1"7(:; t:
S:'

1"

~.::.

r';

npergroup=ntrt;
edit trtresults var
{nsim npergroup or_strat adj
logistic_strat_adj_ts logistic_strat_adj_reject
or_strat_un logistic_strat_un_ts logistic_strat_un_reject
beta strat adj var_beta_strat adj beta strat un var_beta strat un};
append var
{nsim npergroup or_strat adj
logistic_strat adj_ts logistic_strat_adj_reject
or_strat_un logistic_strat_un_ts logistic_strat_un_reject
beta strat adj var_beta strat adj beta strat un var beta strat un};
run;quit;
%mend simulatetrial;
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data trtresultsi
j.nput nsim npergroup or strat adj logistic strat adj ts
logistic_strat_adj_reject or_strat_un logistic_strat_un_ts
logistic_strat_un_reject beta_strat adj var_beta strat adj
beta strat un var beta strat un;

datalineSi
;

runi

%macro completesimulation;
%do samplesize=498%to 1958 %by 112; "Ie Y·=::1.'?·::::'~:
%do nsim=l %to 1000; OM 'CLEAR LOG';

.~~':t~rT·l'~

3~.,7~?;

%simulatetrial(sampsize=&samplesize,Cmildl=0.25,Cmild2= .55,Cmild3
=.75,Cmild4=.85,Cmild5=.93,Cmild6=.95,Cmodl=0.15,Crnod2=.35,Crnod3=
.58,Cmod4=.7,Cmod5=.86,Cmod6=.9,Csevl=0.03,Csev2=.08,Csev3=.15,Cs
ev4=.34,Csev5=.54,Csev6=.75,Tmildl=0.25,Tmild2=.55,TmiId3=.75,Tmi
Id4=.85,Tmild5=.93,Trnild6=.95,Trnodl=0.15,Tmod2=.35,Tmod3=.58,Trnod
4=.7,Tmod5=.86,Tmod6=.9,Tsevl=0.03,Tsev2=.08,Tsev3=.15,Tsev4=.34,
Tsev5=.54,Tsev6=.75)i
96 endi

%end;
%mend completesimulationi

%completes±mulation;
data sliding.notrt;
set trtresultsi
run;

proc means data=sliding.notrt meani
var beta strat un beta strat adj var beta strat un var_beta_strat adj
run;

proc sort data=sliding.notrt;
by npergroupi
run;

proc freq data=sliding.notrt;
tables logistic strat un reject / out=logistic strat un_per;
by npergroup;

run;

proc freq data=sliding.notrti
tables logistic strat adj reject / out=logistic_strat adj_per
by npergroup;

run;
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